AWM
CRMD icon

Avior Wealth Management’s CorMedix CRMD Stock Holding History

Avior Wealth Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$46 – 2590
2024
Q1 		$46 Buy
+11
New +$38 ﹤0.01% 3494

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avior Wealth Management's CRMD Position: Q2 2024 in Review

Avior Wealth Management sold out of CorMedix (CRMD) in Q2 2024, closing a stake of 11 shares — an estimated $46 sold.

Avior Wealth Management first reported a position in CRMD in Q1 2024 and held it in 1 quarter. The position peaked at $46 in Q1 2024. 99 funds tracked by Wall St. Rank hold CRMD as of Q2 2024.

  • Avior Wealth Management reported no remaining CorMedix position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 11 CorMedix shares in Q2 2024, an estimated $46.
  • Avior Wealth Management first reported a position in CorMedix in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's CorMedix position peaked at $46 in Q1 2024.
  • 99 funds tracked by Wall St. Rank held CorMedix as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.